|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001554,
umls-concept:C0014442,
umls-concept:C0017262,
umls-concept:C0086418,
umls-concept:C0144576,
umls-concept:C0205195,
umls-concept:C0442027,
umls-concept:C0520484,
umls-concept:C0596581,
umls-concept:C0879262,
umls-concept:C1280500,
umls-concept:C1704242
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2008-7-28
|
|
pubmed:abstractText |
S-1 is the most effective oral fluoropyrimidine derivative widely used for patients with gastric carcinoma in Japan. Although S-1 plus taxane has been a promising candidate as an effective chemotherapeutic regimen, the mechanisms of its additive or synergistic anticancer effects and changes in gene expression after the administration of these agents have not yet been fully elucidated.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antimetabolites, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Dihydrouracil Dehydrogenase (NADP),
http://linkedlifedata.com/resource/pubmed/chemical/Drug Combinations,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil,
http://linkedlifedata.com/resource/pubmed/chemical/Orotate Phosphoribosyltransferase,
http://linkedlifedata.com/resource/pubmed/chemical/Oxonic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/Paclitaxel,
http://linkedlifedata.com/resource/pubmed/chemical/S 1 (combination),
http://linkedlifedata.com/resource/pubmed/chemical/Tegafur,
http://linkedlifedata.com/resource/pubmed/chemical/Thymidine Phosphorylase,
http://linkedlifedata.com/resource/pubmed/chemical/Thymidylate Synthase,
http://linkedlifedata.com/resource/pubmed/chemical/Uridine Phosphorylase
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1534-4681
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2301-9
|
|
pubmed:dateRevised |
2009-4-16
|
|
pubmed:meshHeading |
pubmed-meshheading:18506536-Animals,
pubmed-meshheading:18506536-Antimetabolites, Antineoplastic,
pubmed-meshheading:18506536-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18506536-Dihydrouracil Dehydrogenase (NADP),
pubmed-meshheading:18506536-Drug Combinations,
pubmed-meshheading:18506536-Drug Synergism,
pubmed-meshheading:18506536-Drug Therapy, Combination,
pubmed-meshheading:18506536-Female,
pubmed-meshheading:18506536-Fluorouracil,
pubmed-meshheading:18506536-Gene Expression,
pubmed-meshheading:18506536-Humans,
pubmed-meshheading:18506536-Male,
pubmed-meshheading:18506536-Mice,
pubmed-meshheading:18506536-Mice, Inbred BALB C,
pubmed-meshheading:18506536-Orotate Phosphoribosyltransferase,
pubmed-meshheading:18506536-Oxonic Acid,
pubmed-meshheading:18506536-Paclitaxel,
pubmed-meshheading:18506536-Stomach Neoplasms,
pubmed-meshheading:18506536-Tegafur,
pubmed-meshheading:18506536-Thymidine Phosphorylase,
pubmed-meshheading:18506536-Thymidylate Synthase,
pubmed-meshheading:18506536-Uridine Phosphorylase,
pubmed-meshheading:18506536-Xenograft Model Antitumor Assays
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Effects of combined administration of DPD-inhibitory oral fluoropyrimidine, S-1, plus paclitaxel on gene expressions of fluoropyrimidine metabolism-related enzymes in human gastric xenografts.
|
|
pubmed:affiliation |
Department of Surgery, Fujita Health University School of Medicine, 1-98 Dengakugakubo Kutsukake-cho, Toyoake, Aichi 470-1192, Japan. ysakurai@fujita-hu.ac.jp
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
